Inovio Pharmaceuticals

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

Retrieved on: 
Tuesday, December 19, 2023
Orexigen Therapeutics, Inovio Pharmaceuticals, CPA, Audit committee, Ernst & Young, MedImmune, Therapy, Controller, BCG, Chairperson, PSINet, Patient, Circassia Group, Compensation, Spark Therapeutics, History, Senior, Management

Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees.

Key Points: 
  • Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees.
  • She is currently serving on the Boards of the publicly traded companies Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.
  • Her past Board experience includes Zymeworks, Spark Therapeutics, Aeras, Orexigen Therapeutics, Circassia Pharmaceuticals, Hyperion Therapeutics, and Ikaria.
  • "I am honored to join the Board of Directors and to serve as Audit Committee Chair to help build a successful future for enGene and patients in need."

Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100

Retrieved on: 
Tuesday, September 19, 2023
Science, DNA, Melamaravakkadu, Biotechnology, COVID-19, Lead, Innovation, Doctor of Philosophy, Messenger, Research and development, SAN, Inovio Pharmaceuticals, R, Health, Industry Dive, Vaccine, Research

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences.

Key Points: 
  • SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences.
  • Dr. Kate Broderick joined the Company in 2022 as Senior Vice President of Research and Development (R&D) at TriLink Biotechnologies, part of Maravai LifeSciences.
  • Dr. Broderick was promoted to lead Maravai’s Science and Innovation Office as Chief Innovation Officer, developing and executing an overarching innovation roadmap and strategy and partnering closely with R&D teams in each corporate operating division to support and drive new ideas.
  • “I am honored to be included among this year’s influential biopharma leaders on the 2023 PharmaVoice 100 list,” said Dr. Broderick.

Bausch + Lomb Solidifies Leadership Team

Retrieved on: 
Tuesday, August 1, 2023
Retail, Health, Other Retail, Specialty, General Health, Pharmaceutical, Optical, Boston Consulting Group, Partnership, Inovio Pharmaceuticals, Bausch & Lomb, PwC, Allergan, Bausch, Waterhouse, Johnson & Johnson Vision, Privacy, Merck, Digital, Merrill (company), NYSE, Management, Saunders

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its executive leadership team including the creation of two new roles.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its executive leadership team including the creation of two new roles.
  • The moves build on a reshuffling announced in early June after Chairman and CEO Brent Saunders, who previously served as CEO from 2010 to 2013, rejoined Bausch + Lomb.
  • “Seizing the opportunity in front of us means acting swiftly, which is why I’ve been so focused on establishing a refreshed leadership team,” said Saunders.
  • Gevgilili is currently chief human resources officer at INOVIO Pharmaceuticals and previously held human resources leadership roles at Allergan, Merck and Merrill Lynch.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Retrieved on: 
Friday, June 23, 2023
MAKE, Stipulation, Philadelphia Division GAA Board, Delaware Court, NO, District court, Notice, Federation, Action for the Republic, Vii, Prejudice, Fee, President's Volunteer Service Award, Hearing, AND, Market Street, Episcopal conference, Approval, Delaware Court of Chancery, FDA, Book, COVID-19, KJSM, Clerk, Judgement, United States district court, Service award, READ, Calendar, Plaintiff, Charter Court Financial Services, Individual, Settlement, Prince William County, Virginia Clerk of Circuit Court, COMMON, Douglas v. U.S. District Court ex rel Talk America, Security (finance), Generic drug, Lease, Tobacco, Insurance, Pharmaceutical industry, Inovio Pharmaceuticals, Court, Demand

THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF STOCKHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.

Key Points: 
  • THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF STOCKHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.
  • IF THE COURT APPROVES THE SETTLEMENT OF THE DERIVATIVE ACTIONS, CURRENT INOVIO STOCKHOLDERS WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE, AND FROM PURSUING RELEASED CLAIMS.
  • This Notice is solely to advise you of the proposed Settlement of the Derivative Actions and of your rights in connection with the proposed Settlement.
  • The Derivative Actions and Demands were brought on behalf of Inovio against certain current and former directors and officers of the Company.

Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors

Retrieved on: 
Monday, April 24, 2023
Amgen, Gilead Sciences, University, Inovio Pharmaceuticals, Cancer, Research, KRON, SAN, Merck, Factorization of polynomials, Pharmaceutical industry, Management

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors.
  • Dr. Dansey brings extensive experience in oncology drug development and a proven track record in the biotechnology industry.
  • He currently serves as president, research and development of Seagen Inc.
    “Roger is an experienced leader in cancer drug development, and we are proud to welcome him to our Board,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.

Europe Human Papillomavirus Vaccine Market Report 2022: Growing Number of HPV Awareness Programs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Infectious Diseases, Health, Medical Supplies, Medical Devices, Wart, Disease, Woman, Penis, Hospital, Vulva, HPV, Merck & Co., Laryngeal papillomatosis, Center for Urban and Regional Analysis, Inovio Pharmaceuticals, Incidence, Vagina, GSK plc, Merck, Infection, COVID-19, Cervical cancer, Wuhan Institute of Biological Products, Anal cancer, Cancer, Vaccine, Application, Vaccitech, Sanofi, Dose

The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
  • The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.

Europe Human Papillomavirus Vaccine Market Report 2022: Sector to Reach $1.59 Billion by 2028 at a 4.9% CAGR

Retrieved on: 
Friday, January 27, 2023
Penis, Merck, Wart, Center for Urban and Regional Analysis, Vagina, Incidence, Infection, Laryngeal papillomatosis, HPV, Hospital, Vulva, Anal cancer, COVID-19, Wuhan Institute of Biological Products, Cancer, GSK plc, Disease, Cervical cancer, Woman, Inovio Pharmaceuticals, Merck & Co., Vaccine, Dose, Application, Vaccitech, Sanofi

The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
  • The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.
  • Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.

Geneos Announces Expansion of Leadership Team

Retrieved on: 
Wednesday, October 12, 2022
Infection, Cros, Therapy, Growth, MS, VP, Conference, SITC, Vaccine, LLC, China Biologic Products, Nature Biotechnology, COVID-19, MBA, Hepatocellular carcinoma, Research, Immunotherapy, Cancer, Knowledge, Immune system, Doctor of Philosophy, MD, MHA, Society, CEO, Inovio Pharmaceuticals, CMO, Forward-looking statement, DNA, FDA, Society for Immunotherapy of Cancer, Pharmaceutical industry, Management, Geneo Grissom

PLYMOUTH MEETING, Pa., Oct. 12, 2022 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that the company has expanded its leadership team and has elected Dr. Laurent Humeau to the company's board of directors.

Key Points: 
  • He brings device related scientific, analytical, manufacturing, and regulatory expertise to the Geneos Board as Geneos prepares for later stage clinical development of its PTCV programs.
  • Geneos has licensed the CELLECTRA devices from Inovio exclusively for delivery of its personalized therapeutic cancer vaccine products.
  • With her expanded leadership role, Ms. Peters now leads all facets of Geneos' clinical and business operations, providing oversight to clinical trials and implementing operational strategy and structure.
  • Geneos has an experienced management team with a track record of success in building immunotherapy-based companies.

Middle East Respiratory Syndrome (MERS) Drug Pipeline Market Insights Report 2022: 12+ Companies and 12+ Pipeline Drugs in the Pipeline Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Health, Other Health, Vaccine, Vaccitech, News, Middle East respiratory syndrome coronavirus outbreak, Technology, ChAdOx1, Disease, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Middle East respiratory syndrome–related coronavirus, II, NDA, MERS, Antibody, Inovio Pharmaceuticals, Infection, Coronavirus, Discovery, Acquisition, Human coronavirus 229E, DNA, Therapy, Pharmaceutical industry

The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.

Key Points: 
  • The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.
  • The assessment part of the report embraces, in depth Middle East Respiratory Syndrome commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Middle East Respiratory Syndrome R&D.
  • The companies which have their Middle East Respiratory Syndrome drug candidates in the most advanced stage, i.e.